Clinical Trial

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

Name: Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer — clinical trial record (NCT06922539)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).

Protocol Amendment History 5 amendments

This ClinicalTrials.gov record has been amended 5 times since 2025-04-03; most recent amendment 2026-07-08.

Status change: Not Yet Recruiting → Recruiting 2025-11-20

Trial Details

NCT Number	NCT06922539
Lead Sponsor	SciTech Development, Inc.
Conditions	Small Cell Lung Cancer
Enrollment	44 participants
Start Date	2025-12-11
Primary Completion	2027-05-01 (estimated)
Study Completion	2028-10-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-10